Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2018
Price : $35 *
At a glance
- Drugs Polyphenon E (Primary)
- Indications Vulvar intraepithelial neoplasia
- Focus Therapeutic Use
- Acronyms EPIVIN
- 01 Dec 2018 Status changed from active, no longer recruiting to completed.
- 17 Jan 2018 Planned End Date changed from 1 Jan 2017 to 30 Nov 2018.
- 17 Jan 2018 Status changed from recruiting to active no longer recruiting.